Edinburgh, UK, 22 June 2020 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP (the “Fund”) at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range from £2 million to £5 million.
{iframe}https://www.bioindustry.org/news-listing/epidarex-capital-closes-new-102-million-uk-venture-fund-to-build-successful-life-science-companies.html#:~:text=EPIDAREX%20CAPITAL%20CLOSES%20NEW%20%C2%A3102%20MILLION%20UK%20VENTURE,BUILD%20SUCCESSFUL%20LIFE%20SCIENCE%20COMPANIES&text=Edinburgh%2C%20UK%2C%2022%20June%202020,%E2%80%9D)%20at%20%C2%A3102.1%20million.{/iframe}